logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Pemphigus Vulgaris Market, By Type (Pemphigus Vulgaris, others), By Diagnostic (Endoscopy, Skin Peeling, and Others) By End User (Biological Therapies, Corticosteroid, and Others) opportunities and forecast 2020-2027

  • DLR2181
  • 19 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Pemphigus is autoimmune disorder. It is group of the rare skin disorders which cause sores, blisters on skin, in mouth, or on genitals. In pemphigus the immune system incorrectly produces the antibodies that can kill healthy cells in skin and mucous membrane. Occasionally it may occur as a side effect of the medication by consuming the drugs of certain blood pressure.

Several factors are expected to drive growth of the market such as growing incidence of cancer, consumption of the tobacco, the unhealthy lifestyle, growing pollution, growing geriatric population and the rising awareness for oral hygiene. According to international pemphigus & the pemphigoid foundation, about 2,500 people in U.S. were suffering from the pemphigus disorder. The worldwide incidences of the pemphigus were 40,000 to 50,000 in 2017.

Segment Overview

Increasing awareness about diseases such as influenza, better health care infrastructure, technological advancements, augmented R&D expenditure, augmented investment by the major players for development of the treatment, increase in the government initiatives and rich product pipeline, are major drivers of global pemphigus vulgaris market. However, high cost of the drug development and

Regional Overview

Geographically, the North America is expected to dominate global pemphigus market. The market growth in the region is accredited to increasing geriatric population suffering from the pemphigus disorder, investment in the research and development and the technological advancement. According to U.S. National Institute of Health almost 32 cases per million of the population population were reported for the pemphigus in the US.

Europe is anticipated to be second largest market in globe owing to increasing number of the geriatric populations, growing government expenditure for the oral hygiene, rising disposable income and growing use of tobacco in the region. According to data by Europe PMC, in 2017, occurrences of the pemphigus ranging from the 0.5 cases per million of the population in the Germany to almost 8 cases per million of the population in Greece.

Asia-Pacific is expected to be fastest growing market owed to growing prevalence of the pemphigus, and the oral related problems in developing countries, growing disposable income and the growing healthcare expenditure.

The Middle East and Africa is anticipated to account for lowest market share in tglobal pemphigus market owing to lack of technical knowledge, the low development, and the poor medical facilities in these developing economies.

Competitor overview

Major players operating in global pemphigus market include Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Alexion, Vifor Pharma Management Ltd., argenx, Genentech, Inc., and Principia Biopharma.

Key Players
  1. Novartis Pharmaceuticals,
  2. Hoffmann-La Roche,
  3. Principia Biopharma, Inc,
  4. Argenx, Sanofi S.A.,
  5. Pfizer Inc.,
  6. Teligent Inc,
  7. GlaxoSmithKline LLC,
  8. Teva Pharmaceutical Industries

Market Segmentation

By Type
  • Pemphigus Vulgaris
  • Pemphigus Foliaceus
  • Pemphigus Vegetans
  • Paraneoplastic Pemphigus
  • Other
By Diagnostic
  • Skin peeling
  • Run blood tests
  • Skin biopsy
  • Endoscopy
By End User
  • Laboratories
  • Academic and Research Institutes
  • Hospitals and Clinics
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Report Prologue 11

    2 Market Introduction 13

    • 2.1 Scope of Study 14
    • 2.2 Research Objective 14
    • 2.3 List of Assumptions 14

    3 Research Methodology 16

    • 3.1 Research Process 17
    • 3.2 Primary Research 17
    • 3.3 Secondary Research 18
    • 3.4 Market Size Estimation 20

    4 Market Dynamics 21

    • 4.1 Introduction 22
    • 4.2 Drivers 22
      • 4.2.1 Increasing prevalence of pemphigus vulgaris globally 22
      • 4.2.2 Growing financial support by various private and government organizations for research of diseases 22
      • 4.2.3 Increasing geriatric population 22
    • 4.3 Restraints 23
      • 4.3.1 Lack of awareness among the countries 23
      • 4.3.2 High cost of treatment 23
    • 4.4 Opportunities 23
      • 4.4.1 Advancements in treatments 23
    • 4.5 Challenge 23
      • 4.5.1 Adverse side-effects of the treatment 23

    5 Market Factor Analysis 24

    • 5.1 Overview 25
      • 5.1.1 R&D 25
      • 5.1.2 Manufacturing 25
      • 5.1.3 Distribution & Sales 25
      • 5.1.4 Post-Sales Monitoring 26
    • 5.2 Porter’s Five Forces Model 26
      • 5.2.1 Overview 26
      • 5.2.2 Bargaining Power of Suppliers 27
      • 5.2.3 Bargaining Power of Buyers 27
      • 5.2.4 Threat of New Entrants 27
    • 5.3 Threat of Substitutes 27
    • 5.4 Intensity of Rivalry 27
    • 5.5 Investment Opportunity Analysis 28

    6 Global Pemphigus Vulgaris Market, By Treatment 29

    • 6.1 Introduction 30
    • 6.2 Corticosteroids 32
    • 6.3 Immunosuppressants 32
    • 6.4 Biological Therapies 33
    • 6.5 Intravenous Immunoglobulin (IVIG) Therapy 33

    7 Global Pemphigus Vulgaris Market, By Route of Administration 34

    • 7.1 Introduction 35
    • 7.2 Intravenous 36
    • 7.3 Subcutaneous 36
    • 7.4 Oral 36

    8 Global Pemphigus Vulgaris Market, By End-user 37

    • 8.1 Introduction 38
    • 8.2 Hospitals & Clinics 39
    • 8.3 Specialty Dermatology Clinics 39
    • 8.4 Research & Academic Laboratories 39

    9 Global Pemphigus Vulgaris Market, By Region 40

    • 9.1 Introduction 41
    • 9.2 Americas 43
      • 9.2.1 North America 45
        • 9.2.1.1 U.S 47
        • 9.2.1.2 Canada 48
      • 9.2.2 South America 49
    • 9.3 Europe 50
      • 9.3.1 Western Europe 52
        • 9.3.1.1 Germany 54
        • 9.3.1.2 U.K 55
        • 9.3.1.3 France 56
        • 9.3.1.4 Italy 57
        • 9.3.1.5 Spain 58
        • 9.3.1.6 Rest of Western Europe 59
      • 9.3.2 Eastern Europe 60
    • 9.4 Asia Pacific 61
      • 9.4.1 Japan 63
      • 9.4.2 China 64
      • 9.4.3 India 65
      • 9.4.4 Australia 66
      • 9.4.5 Republic of Korea 67
      • 9.4.6 Rest of Asia Pacific 68
    • 9.5 Rest of the World 69

    10 Competitive Landscape 70

    • 10.1 Introduction 71

    11 Company Profiles 72

    • 11.1 Almirall, S.A 73
      • 11.1.1 Company Overview 73
      • 11.1.2 Financial Overview 73
      • 11.1.3 Products/Services Offered 74
      • 11.1.4 Key Developments 74
      • 11.1.5 SWOT Analysis 74
      • 11.1.6 Key Strategy 74
    • 11.2 Argenx SE 75
      • 11.2.1 Company Overview 75
      • 11.2.2 Financial Overview 75
      • 11.2.3 Products/Services Offered 75
      • 11.2.4 Key Developments 75
      • 11.2.5 SWOT Analysis 76
      • 11.2.6 Key Strategy 76
    • 11.3 Biogen Inc. 77
      • 11.3.1 Company Overview 77
      • 11.3.2 Financial Overview 77
      • 11.3.3 Products/Services Offered 78
      • 11.3.4 Key Developments 78
      • 11.3.5 SWOT Analysis 78
      • 11.3.6 Key Strategy 78
    • 11.4 F. Hoffmann-La Roche 79
      • 11.4.1 Company Overview 79
      • 11.4.2 Financial Overview 79
      • 11.4.3 Products/Services Offered 80
      • 11.4.4 SWOT Analysis 80
      • 11.4.5 Key Strategy 80
    • 11.5 Syntimmune 81
      • 11.5.1 Company Overview 81
      • 11.5.2 Financial Overview 81
      • 11.5.3 Products/Services Offered 82
      • 11.5.4 Key Developments 82
      • 11.5.5 SWOT Analysis 82
      • 11.5.6 Key Strategy 82
    • 11.6 Pfizer Inc. 83
      • 11.6.1 Company Overview 83
      • 11.6.2 Financial Overview 83
      • 11.6.3 Products/Services Offered 84
      • 11.6.4 Key Developments 84
      • 11.6.5 SWOT Analysis 84
      • 11.6.6 Key Strategy 84
    • 11.7 Novartis AG 85
      • 11.7.1 Company Overview 85
      • 11.7.2 Financial Overview 85
      • 11.7.3 Products/Services Offered 86
      • 11.7.4 Key Developments 86
      • 11.7.5 SWOT Analysis 86
      • 11.7.6 Key Strategy 86
    • 11.8 Sanofi 87
      • 11.8.1 Company Overview 87
      • 11.8.2 Financial Overview 87
      • 11.8.3 Products/Services Offered 88
      • 11.8.4 Key Developments 88
      • 11.8.5 SWOT Analysis 88
      • 11.8.6 Key Strategy 88
    • 11.9 Janssen Global Services, LLC 89
      • 11.9.1 Company Overview 89
      • 11.9.2 Financial Overview 89
      • 11.9.3 Products/Services Offered 90
      • 11.9.4 Key Developments 90
      • 11.9.5 SWOT Analysis 90
      • 11.9.6 Key Strategy 90
    • 11.10 Principia Biopharma 91
      • 11.10.1 Company Overview 91
      • 11.10.2 Financial Overview 91
      • 11.10.3 Products/Services Offered 91
      • 11.10.4 Key Developments 91
      • 11.10.5 SWOT Analysis 91
      • 11.10.6 Key Strategy 91

    12 Appendix 92

    • 12.1 Discussion Blue Print 93

    Report You Might be Interested